Home
Toolbox
Resource
Workflow
Tutorials
Citations
Downloads
Mutation Al-Predictor Flow
Gene-to-Mutation Flow
News & Insights
Genetic Encyclopedia
Frontiers
Industry Insights
Case Studies
About Us
About the Site
Contact Us
Private Policy
User Agreement
COL4A5 c.1390G>A
ALS1
DMD c.1332-11868C>G
TP53
肌萎缩侧索硬化症1型
USH2A c.8559-2A>G
囊性纤维化
Log In
|
Sign Up
中文
人类
LAIR1 - Leukocyte Associated Immunoglobulin Like Receptor 1
Alias:
CD305
LAIR-1
Create a favorites folder
Cancel
Confirm
Add To Favorites
Select a favorites
Description
New favorites >>
Cancel
Confirm
Favorite
Basic Information
Sequence Homology
Related Diseases and Mutations
Transcripts & Proteins
Gene Expression
Interactions
Related Mouse Models
Related Drugs
References Literature
这个基因编码的蛋白质是一种抑制性受体,位于外周单核细胞上,包括自然杀伤细胞、T细胞和B细胞。抑制性受体调节免疫反应,防止被识别为自身的细胞溶解。该基因既是免疫球蛋白超家族也是白细胞相关抑制性受体家族的成员。该基因位于19号染色体q13.4区域,被称为白细胞受体簇,至少包含29个编码免疫球蛋白超家族的白细胞表达受体的基因。编码的蛋白质已被鉴定为酪氨酸磷酸酶SHP-1的锚定物,并可能在髓系白血病中诱导细胞死亡。可变剪接产生多种转录变异体。[RefSeq,2014年1月提供]
Related ID:
NCBI:3903
ENSEMBL:ENSG00000167613
HGNC:6477
UNIPROT:Q6GTX8
OMIM:602992
Basic Information
NCBI
Transcripts
Exons
Length
MW (kDa)
Mutations
Related Diseases
Related Mouse Models
Reference
3903
10
10
24705 bp
31.47
7
--
6
20
LAIR1 Genetics information (-)
GRCh38
Sequence Homology
Related Diseases and Mutations
#
Disease
Anatomical Category
Score
Mutations
No data available
Transcripts & Proteins
Table View
Tile View
#
Transcript
Length(nt)
Exon Count
CDS(bp)
Protein
Length(aa)
No data available
* This data comes from NCBI.
Gene Expression
Tissue-specific RNA expression
Organ
Abundance
Alphabetical
Cell-specific RNA expression
Organ
Abundance
Alphabetical
Interactions
Reset
Acting
Regulation
Detail
Mechanism
Target
Residues
Reference
Score
No data available
Related Mouse Models
Type
Name
MGI
Strain of Origin
Publications
Mutations
No data available
Related Drugs
Name
CAS Number
Status
Phase
Link
No data available
References Literature
Title
PMID
Journal
Year
IF
No Data Found!
Wechat
Mutation Direct
Sequence
Comparison
Al agent
Tutorials
Back to top